RNAZ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 03:24):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
今日成交量	1.07M
平均成交量	509 146
市值	3.94M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00200 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

音量相关性

長: 0.36 (neutral)

短: 0.27 (neutral)

Signal:(43.991) Neutral

TransCode Therapeutics, 相关性

10 最正相关
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 最负相关
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

TransCode Therapeutics, 相关性 - 货币/商品

0.47
( neutral )

0.42
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.84
( strong negative )

-0.42
( neutral )

TransCode Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
营收:	$0
毛利润:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
营收:	$0
毛利润:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.